SUB12581MIG

DRUG2 trials

Sponsors

Eli Lilly & Co.

Conditions

Alopecia AreataNon-Segmental Vitiligo (NSV)Vitiligo

Phase 2

J5D-MC-FPAD: A Phase 2a, Randomized, 24-Week, Multicenter, Double-Blind, Placebo-Controlled Proof-of-Concept Study to Investigate Efficacy and Safety of LY4005130 in Adult Participants with Non-Segmental Vitiligo

Not yet recruitingCTIS2025-524726-18-00

Eli Lilly & Co.Non-Segmental Vitiligo (NSV), Vitiligo

Target: 6Updated: 2026-05-29

J5D-MC-FPAC: A Phase 2a, Randomized, Multicenter, Double-Blind, Placebo-Controlled Proof of Concept Study to Investigate Efficacy and Safety of LY4005130 in Adult Participants With Severe Alopecia Areata

Not yet recruitingCTIS2025-524727-41-00

Eli Lilly & Co.Alopecia Areata

Target: 5Updated: 2026-06-08